At Least 14 US States Have Built Their Own Peptide Rules Beyond FDA — Creating a Regulatory Patchwork

The FDA's expected reclassification of 14 peptides from Category 2 back to Category 1 — a move prompted by Health and Human Services Secretary Robert F. Kennedy Jr.'s February 2026 directive — has dominated headlines as the most significant shift in peptide access in years. But a less visible regulatory story is unfolding at the state level, where at least 14 states have enacted their own peptide-related restrictions that go beyond federal rules, creating a patchwork of conflicting standards that complicates access for patients, clinicians, and compounding pharmacies alike.

Federal FDA regulations establish a floor for peptide regulation, not a ceiling. States retain broad authority to impose additional requirements on compounding pharmacies operating within their borders, and many have exercised that authority aggressively in the wake of the original Category 2 designations in 2023.

A map of contradictions

The state-level landscape defies easy summary. Some states have added prescribing requirements — mandating that certain peptides can only be prescribed by specific specialist physicians. Others have imposed additional testing requirements on compounding pharmacies, requiring third-party potency and sterility verification beyond what federal 503A and 503B rules demand. A handful have banned specific compounds outright, regardless of their federal status.

The result is that a peptide like BPC-157, a synthetic peptide derived from a protein found in gastric juice that has been studied for wound healing and tissue repair, may be legally prescribed and compounded in Texas but face additional restrictions or outright prohibition in California — even after the FDA's reclassification takes effect.

Telemedicine and multi-state care

The patchwork creates acute problems for the growing telemedicine-based peptide therapy industry. Clinicians prescribing across state lines must navigate not only federal DEA and FDA rules but also the specific compounding and prescribing laws of both the prescriber's state and the patient's state. Multi-state health systems face compliance burdens that smaller operations may struggle to manage.

"The federal reclassification is necessary but not sufficient," noted the Alliance for Pharmacy Compounding in a recent statement. "Until states harmonize their rules with the new federal framework, patients will continue to face uneven access depending on their zip code."

What comes next

Industry groups are pushing for a coordinated state-level response. The National Association of Boards of Pharmacy (NABP) has convened working groups to develop model legislation that states could adopt, but the process is slow. Meanwhile, the FDA's reclassification itself remains in a public comment period, with final implementation expected by mid-2026.

For patients currently seeking compounded peptide therapies, the practical advice remains the same: work with a licensed physician and a state-licensed compounding pharmacy, verify the specific legal status of any peptide in your state, and be skeptical of any vendor operating outside the regulated pharmacy system.